iPSC-MSCs and islet allograft tolerance

Oncotarget. 2015 May 10;6(13):10669-70. doi: 10.18632/oncotarget.4050.

Authors

Tong-Song Wang¹, Pan-Pan Cheng², Zhong-Quan Qi³

Affiliations

¹ School of Science, Shantou University, Shantou City, Guangdong Province, PR China.
² Qingdao Municipal Centers for Disease Control and Prevention, Qingdao City, Shandong Province, PR China.
³ Organ Transplantation Institute, Medical College, Xiamen University, Xiamen City, Fujian Province, PR China.

No abstract available

Publication types

Editorial

MeSH terms

Allografts
Animals
Graft Rejection / immunology
Graft Rejection / prevention & control
Graft Survival
Humans
Immunosuppressive Agents / pharmacology
Induced Pluripotent Stem Cells / immunology*
Induced Pluripotent Stem Cells / metabolism
Induced Pluripotent Stem Cells / transplantation*
Islets of Langerhans Transplantation*
Mesenchymal Stem Cell Transplantation*
Mesenchymal Stem Cells / immunology*
Mesenchymal Stem Cells / metabolism
Phenotype
Sirolimus / pharmacology
Transforming Growth Factor beta / immunology
Transforming Growth Factor beta / metabolism
Transplantation Tolerance* / drug effects

Substances

Immunosuppressive Agents
Transforming Growth Factor beta
Sirolimus